RYAN ARTHUR F 4

What Happened

• Ryan Arthur F, a director of Regeneron Pharmaceuticals (REGN), sold 100 shares in multiple open-market transactions on February 9, 2026, realizing approximately $77,854 total. Individual trade prices ranged roughly from $775.63 to $787.82 per share (grouped volume‑weighted averages reported for several blocks).

Key Details

• Transaction date: February 9, 2026; Form 4 filed February 11, 2026 (timely).
• Transaction type/code: Open-market sales (S).
• Shares sold: 100 total across multiple trades; total proceeds ≈ $77,854.
• Price range: about $775.63 to $787.82 per share; several VWAPs reported for blocks of 10, 57, 12, 5, 5 and 3 shares (see footnotes F2–F7 in the filing).
• Plan/footnote: Dispositions were made pursuant to a Rule 10b5-1(c) trading plan adopted Oct 31, 2025 (footnote F1).
• Shares owned after transaction: not specified in the summary provided; consult the full filing for post-transaction holdings.

Context

• These were outright sales under a pre-arranged 10b5-1 plan, which indicates the trades were planned in advance and are generally considered routine rather than a contemporaneous signal of insider sentiment. Sales (S) are less informative about future prospects than purchases, which can indicate increased insider confidence.